申请人:Zeneca Limited
公开号:US05641793A1
公开(公告)日:1997-06-24
The invention concerns pharmaceuticaly useful compounds of the formula I, in which Q, A.sup.1, A.sup.2, A.sup.3, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have any of the meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutically compositions containing them. The novel compounds possess endothelin receptor antagonist activity and are useful in the treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.
这项发明涉及具有以下公式I的药用化合物,其中Q、A.sup.1、A.sup.2、A.sup.3、R.sup.1、R.sup.2、R.sup.3和R.sup.4具有此处定义的任何含义,以及它们的药用可接受盐和含有它们的药用组合物。这些新颖化合物具有内皮素受体拮抗活性,并且在治疗内皮素水平升高或异常的疾病或医疗状况中具有重要的因果作用。该发明还涉及新化合物的制备过程以及化合物在医疗治疗中的应用。